Actively Recruiting

Age: 18Years +
All Genders
ID06625203

Multi Omics and Spatial Atlas in Cancer: An International Observational Study Collecting Clinical, Imaging, and Molecular Data

Led by OWKIN · Updated on 2024-10-03

7000

Participants Needed

5

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Cancer is a leading cause of illness and death worldwide, with treatment challenges arising from the complex interactions between cancer cells and their surrounding environment, known as the tumor microenvironment (TME). Recent advances in artificial intelligence and sequencing technologies have opened new possibilities for personalized treatment strategies by better understanding these complex biological networks. This research focuses on characterizing the TME and its impact on treatment resistance and sensitivity, including immunotherapy and targeted therapies, across various cancer types. The MOSAIC study is an international, non-interventional research project collecting extensive molecular and clinical data from over 2,000 tumor samples from patients with different cancers. The study gathers multiple types of data, including clinical information, microscopic images, and spatial transcriptomics, with additional data from RNA sequencing, whole exome sequencing, and single-cell transcriptomics when possible. Tumor samples must be formalin fixed and paraffin embedded (FFPE) and are sourced from previous biopsies or surgical resections stored in pathology archives. This approach aims to create a detailed atlas of cancer and its microenvironment to support new drug discovery and patient subgroup identification. Participants diagnosed with eligible cancers provide archived tumor tissue and associated clinical data for analysis. Researchers will assess gene and protein features linked to potential drug targets and novel biomarkers, as well as biological pathways related to patient outcomes and treatment responses. The study involves long-term follow-up, with data collection continuing up to 16 years from diagnosis. This comprehensive data gathering aims to improve understanding of cancer biology and support the development of personalized treatment options while monitoring safety and outcomes over time.

CONDITIONS

Brief Title

A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient was over 18 years old at the time of sample collection or consent.
  • Patient has provided informed consent or non-opposition form for exploratory research.
  • Confirmed diagnosis of the relevant tumor type based on international criteria.
  • Availability of formalin fixed paraffin embedded (FFPE) tissue sample suitable for data generation.
  • Availability of associated clinical data.
  • Tissue block meets criteria: expected tumor type; for solid tumors, tumor cell content 40%-80% on H&E section; for diffuse large B cell lymphoma, minimum 80% high-grade component on H&E; tissue thickness over 125 micrometers if possible; tumor sample less than 10 years old.
  • Additional specific inclusion criteria may apply per cancer sub-cohort.
Not Eligible

You will not qualify if you...

  • Samples without preserved tissue architecture, such as cytologies and cytoblocks.
  • Additional specific exclusion criteria may apply per cancer sub-cohort, e.g., histological subtype or history of immunosuppression.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Diagnostic Evaluation

Duration - Up to 16 years

Participants provide archived tissue samples and associated clinical data for analysis.

Long-term Monitoring

Duration - Up to 16 years

Participants are observed over time to collect clinical outcomes and biomarker data related to their cancer diagnosis.

Trial Site Locations

Total: 5 locations

1

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15238

Actively Recruiting

2

Gustave Roussy

Paris, France

Actively Recruiting

3

Charité - Universitätsmedizin Berlin

Berlin, Germany

Actively Recruiting

4

Universiy Hospital Erlangen & FAU Erlangen-Nürnberg

Erlangen, Germany

Actively Recruiting

5

Centre Hospitalier Universitaire Vaudois

Lausanne, Switzerland

Actively Recruiting

Loading map...

Research Team

H

Hubert Chaperon

G

Ginevra Ferrarini

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

A Phase 1 Dose-Escalation and Expansion Study of Intratumora...

Triple Negative Breast Cancer

Actively Recruiting

16 locations

A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study...

B-cell Malignancy

Actively Recruiting

130 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer.

Maxime Meylan, Florent Petitprez, Etienne Becht...

https://pubmed.ncbi.nlm.nih.gov/35231421